Company news

Share this article:
According to an internal memo, Pfizer is planning to end manufacturing of heart disease medications, Forbes reported, while also scaling back development of anemia, osteoporosis, liver, muscle, obesity and peripheral artery disease treatments. The company will instead focus on five therapeutic areas: Alzheimer's; diabetes, immune disorders and inflammation; cancer; pain and mental illness.

In an effort to control costs, GlaxoSmithKline may cut as many as 850 R&D jobs in the US and UK, according to a Wall Street Journal report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.